Top-News
Freitag,
27.05.2016 08:35
von
GlobeNewswire
| Aufrufe: 142
Annual General Meeting of Active Biotech AB
Eine Rakete, die aus einem Laptop hervorgeht als Symbol für Start-up-Ideen (Symbolbild).
© peshkov / iStock / Getty Images Plus / Getty Images
The Annual General Meeting of Active Biotech was held on May 26, 2016.
In accordance with the Board of Directors' proposal, it was resolved that no dividend would be paid.
The board members and the managing director were discharged from liability with respect to their management of the company for 2015.
In accordance with the Election Committee's proposal, the Board members Mats Arnhög, Magnhild Sandberg-Wollheim, Peter Sjöstrand and Peter Thelin were re-elected. The Meeting also resolved to re-elect Mats Arnhög as Chairman of the Board. KPMG AB was re-elected as auditor.
Furthermore, in accordance with the Election Committee's proposal, the Meeting resolved that the Election Committee shall be composed of representatives for the three largest owners, as per the end of September, 2016, as well as the Chairman of the Board.
The Meeting approved the Board's proposal concerning guidelines for remuneration to the President and other senior executives. The guidelines conform to the principles applied to date.
In accordance with the Board's proposal, the Meeting resolved to authorize the Board, for a period that does not extend past the date of the next Annual General Meeting, to resolve on the issue of not more than seven million new shares and/or convertibles with the corresponding dilution effect, with or without pre-emptive rights for the company's shareholders.
Lund, May 27, 2016
Active Biotech AB (publ)
Tomas Leanderson
President and CEO
For further information, please contact:
Hans Kolam, CFO
Tel +46 46 19 20 44
Active Biotech AB (publ) (Nasdaq Stockholm: ACTI) is a biotechnology company with focus on neurodegenerative/inflammatory diseases and cancer. Laquinimod, an orally administered small molecule with unique immunomodulatory properties, is in pivotal Phase 3 development for the treatment of relapsing remitting multiple sclerosis. Also, laquinimod is in Phase 2 development for the treatment of primary progressive multiple sclerosis and Huntington's disease. Furthermore, commercial activities are conducted for the tasquinimod, SILC, ANYARA and paquinimod projects. Please visit www.activebiotech.com for more information.
Active Biotech AB
(Corp. Reg. No. 556223-9227)
Box 724, SE-220 07 Lund, Sweden
Tel: +46 (0)46 19 20 00
Active Biotech is obligated to publish the information contained in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. This information was provided to the media for publication at 8:30 a.m. CET on May 27, 2016.
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Active Biotech via Globenewswire
HUG#2015738
Werbung
Mehr Nachrichten zur Active Biotech Aktie kostenlos abonnieren
E-Mail-Adresse
Bitte überprüfe deine die E-Mail-Adresse.
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)
-1
Vielen Dank, dass du dich für unseren Newsletter angemeldet hast. Du erhältst in Kürze eine E-Mail mit einem Aktivierungslink.
Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.
Andere Nutzer interessierten sich auch für folgende News
09:12 - PR Newswire
